dasabuvir (Exviera) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B palm polymerase inhibitor. It is used in the treatment of adult patients with chronic hepatitis C virus infection in combination with ombitasvir, paritaprevir, and ritonavir as the combination product Viekira Pak. Viekira PAK combines three direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle. Dasabuvir is extensively evaluated in large clinical trials and shown excellent sustained virological response among hepatitis C virus genotype1 patient population in combination with other oral direct acting antivirals, with good safety profile and tolerance.   NCATS

  • SMILES: COc1c(cc(cc1C(C)(C)C)N2C=CC(=O)NC2=O)c3ccc4cc(NS(=O)(=O)C)ccc4c3
  • Mol. Mass: 493.59
  • ALogP: 4.02
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( ritonavir (Norvir), ombitasvir (Viekira Pak), paritaprevir (viekira pak), dasabuvir (Exviera) - other name: dasabuvir, ombitasvir, paritaprevir, and ritonavir )
abt-333 | dasabuvir | dasabuvir sodium | dasabuvir sodium monohydrate | exviera | n-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide | sodium 3-(3-tert-butyl-4-methoxy-5-{6­ [(methylsulfonyl)amino]naphthalene-2-yl}phenyl)-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-ide hydrate (1:1:1)


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue